Daily Respiratory Research Analysis
Analyzed 228 papers and selected 3 impactful papers.
Summary
Analyzed 228 papers and selected 3 impactful articles.
Selected Articles
1. Inflammatory immune modulators of AML lung infiltration and respiratory failure.
Spatial and single-cell profiling of AML-infiltrated lungs revealed inflammatory remodeling with loss of tissue integrity. Steroids reduced AML lung infiltration and improved oxygenation. Mechanistically, Galectin-9 (Lgals9) and IL-33/ST2 (IL-1RL1) axes mediated leukemic lung interactions; targeting either axis decreased overall AML burden and lung infiltration.
Impact: Identifies actionable immune pathways (Galectin‑9 and IL‑33) that drive leukemic lung infiltration and respiratory failure, providing immediate translational targets beyond empiric steroids.
Clinical Implications: For AML patients with respiratory failure due to lung infiltration, systemic steroids may have a mechanistic rationale; Galectin‑9 or IL‑33/ST2 blockade emerges as a potential therapeutic strategy warranting early-phase trials and biomarker-guided patient selection.
Key Findings
- Spatial and single-cell mapping showed inflammatory remodeling with impaired tissue integrity in AML-infiltrated lungs.
- Systemic steroids reduced AML lung infiltration, improved oxygenation, and enhanced pulmonary function.
- Lgals9 (Galectin‑9) and IL‑33/IL‑1RL1 axes mediated cell–cell interactions; targeting either axis decreased AML burden and lung infiltration.
Methodological Strengths
- Integration of spatial transcriptomics and single-cell resolution profiling of the leukemic lung microenvironment
- Mechanistic validation with pharmacologic interventions (steroids; Galectin‑9 and IL‑33 axis targeting) and functional readouts (oxygenation, lung function)
Limitations
- Predominantly preclinical mechanistic work; human interventional data are lacking
- Sample sizes and heterogeneity across AML subtypes and treatment histories are not detailed
Future Directions: Prospective biomarker studies to identify patients with Galectin‑9/IL‑33 axis activation; early-phase trials of IL‑33/ST2 or Galectin‑9 blockade in AML-related respiratory failure; integration with standard chemotherapy or hypomethylating agents.
Acute myeloid leukemia (AML) is a blood cancer with poor survival outcomes. Acute respiratory failure frequently occurs due to leukemia infiltration of the lungs. Underlying mechanisms remain unexplored and therapeutic interventions remain empiric. Here we map the AML lung microenvironment at spatial and single-cell resolution. We show that extensive remodeling is coupled with inflammation and impaired tissue integrity and function. Steroid treatment significantly reduces AML burden and lung infiltra
2. Sialic acid-anchored haemagglutinin stalk neutralizing antibody M-SiaB enhances protection against highly pathogenic influenza H5N1/Texas/2024.
By fusing an HA-stalk mAb with a sialic acid receptor-binding module, M‑SiaB increased neutralization potency 4–20× across diverse authentic influenza viruses and blocked attachment, entry, and release. Intranasal M‑SiaB markedly protected mice against nasal challenges with H1N1/PR8 and H5N1/Texas/2024; a single dose preserved survival up to 21 days after lethal H5N1 challenge.
Impact: Introduces a dual-target antibody design that broadens and potentiates influenza neutralization with strong in vivo protection against contemporary H5N1, addressing an urgent pandemic threat.
Clinical Implications: Supports development of intranasal prophylaxis or early treatment for high-risk exposures to divergent influenza (e.g., H5N1). Requires IND‑enabling safety/toxicity, PK/PD, manufacturability, and resistance mapping before clinical deployment.
Key Findings
- Engineering an HA-stalk mAb fused to a sialic acid receptor-binding domain increased neutralization potency 4–20× across diverse authentic influenza strains.
- M‑SiaB inhibited multiple stages of the viral life cycle, including attachment, entry, and release.
- Intranasal administration conferred robust protection against H1N1/PR8 and H5N1/Texas/2024, with single-dose survival after lethal H5N1 challenge lasting up to 21 days.
Methodological Strengths
- Use of authentic influenza strains and lethal in vivo challenge models with survival endpoints
- Mechanistic assays demonstrating inhibition at multiple viral life-cycle stages and effective intranasal delivery
Limitations
- Preclinical animal data; human safety, PK/PD, and immunogenicity unknown
- Potential for escape mutations not fully characterized; manufacturing scalability not addressed
Future Directions: Conduct IND‑enabling studies, aerosolization/CMC optimization, and phase 1 trials; evaluate combination with neuraminidase inhibitors; map resistance and breadth across zoonotic strains.
The recently emerged cattle H5N1/Texas/2024 strain highlights the need for effective prophylactic and therapeutic drug interventions, yet most existing neutralizing antibodies (NAbs) have limited efficacy against genetically divergent pathogenic influenza viruses. Here we engineer a sialic acid-anchored tandem M-SiaB by fusing a hemagglutinin (HA) stalk-specific monoclonal NAb with a sialic acid-receptor-binding domain (SiaB). M-SiaB shows 4- to 20-fold greater neutralizing potency against diver
3. Nasal Continuous Positive Airway Pressure vs Nasal Intermittent Positive Pressure Ventilation in Preterm Infants With Respiratory Distress Syndrome: A Randomized Clinical Trial.
In extremely preterm infants with RDS, initial NIPPV plus MISA halved early NIV failure compared with NCPAP (13.2% vs 26.1%), crossing the noninferiority margin and establishing NCPAP inferiority. Seven-day failure was also lower with NIPPV; major complications were similar.
Impact: This well-conducted multicenter RCT directly informs first-line noninvasive ventilation strategy in a high-risk neonatal population and is likely to influence NICU practice.
Clinical Implications: NIPPV should be preferred over NCPAP as initial support before MISA in extremely preterm infants with RDS to reduce early intubation; long-term neurodevelopmental and BPD outcomes require follow-up.
Key Findings
- Early NIV failure within 72 hours: 26.1% (NCPAP) vs 13.2% (NIPPV); adjusted risk difference 12.8% (95% CI 4.2–21.6), crossing the 10% noninferiority margin
- NIV failure within 7 days was lower with NIPPV (15.1%) vs NCPAP (27.5%); risk difference 12.4% (95% CI 3.4–21.4)
- Most major complications (e.g., pneumothorax, BPD) did not differ significantly between groups
Methodological Strengths
- Multicenter, randomized, prespecified noninferiority design with O'Brien-Fleming alpha control
- Standardized early MISA protocol across sites and clinically meaningful primary endpoint
Limitations
- Early termination at 32.5% of planned enrollment limits precision and long-term outcome assessment
- Generalizability to different ventilator settings/interfaces or centers outside the study context may vary
Future Directions: Evaluate neurodevelopment, bronchopulmonary dysplasia, and long-term respiratory outcomes; assess implementation across diverse NICU settings and optimize NIPPV parameters.
IMPORTANCE: Respiratory distress syndrome (RDS) remains a leading cause of morbidity and mortality in preterm infants. Evidence regarding the optimal initial noninvasive ventilation (NIV) mode for extremely preterm infants (<30 weeks' gestation) with RDS is inconsistent. OBJECTIVE: To determine whether nasal continuous positive airway pressure (NCPAP) is noninferior to nasal intermittent positive pressure ventilation (NIPPV) as primary respiratory support before minimally invasive surfactant administration (MISA) for reducing intubation within 72 hours in preterm infants with RDS. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, noninferiority randomized clinical trial was conducted across 11 tertiary neonatal intensive care units in China from December 2021 to October 2024. The trial was designed to enroll 960 infants but was stopped early after enrolling 312 (32.5% of the target) based on prespecified stopping criteria. The enrolled participants were spontaneously breathing preterm infants at 24 to 29+6 weeks' gestation with a diagnosis of RDS requiring noninvasive respiratory support after birth. Data were analyzed from January 7 to May 9, 2025. INTERVENTION: Infants were randomized 1:1 to receive NCPAP or NIPPV as initial respiratory support. All received MISA within 120 minutes after birth via a 1.67-mm catheter. MAIN OUTCOMES AND MEASURES: The primary outcome was NIV failure, defined as requiring intubation and invasive mechanical ventilation within 72 hours after birth. The noninferiority margin was set at a 10% risk difference. Secondary outcomes included NIV failure within 7 days, surfactant redosing, and major complications (eg, pneumothorax, bronchopulmonary dysplasia). RESULTS: A total of 312 preterm infants (median [IQR] gestational age, 28.0 [28.6-29.4] weeks; 174 boys [55.8%]) were randomized to the NCPAP group (153 infants) or the NIPPV group (159 infants). NIV failure within 72 hours occurred in 40 infants (26.1%) in the NCPAP group vs 21 infants (13.2%) in the NIPPV group (adjusted risk difference, 12.8%; 95% CI, 4.2%-21.6%; P = .004; O'Brien-Fleming adjusted α = .005), exceeding the noninferiority margin and conclusively demonstrating inferiority of NCPAP. NIV failure within 7 days was also higher in the NCPAP group (42 infants [27.5%] vs 24 infants [15.1%]; risk difference, 12.4%; 95% CI, 3.4%-21.4%; P = .008). No significant differences were observed between groups for most complications. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of preterm infants with RDS, NIPPV with MISA as initial respiratory support significantly reduced NIV failure within 72 hours compared with NCPAP. These findings suggest that NIPPV may be the preferred primary respiratory strategy for this high-risk population, although further evaluation of long-term outcomes is warranted due to early trial termination. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05137340.